However, ESs are generally considered as immunologically inert tumors with a low mutational burden and lack of high-affinity neoepitopes, low PD-L1 expression, lack of potentially tumor-reactive T cells in the tumor microenvironment, and HLA loss [371,372,373]. This evidence concerns the gene CD274 and neoplasm.